Dihexa vs Semax

Overview

Dihexa and Semax are both peptides researched for cognitive effects but with entirely different mechanisms and evidence bases. Dihexa is an angiotensin IV analog that modulates the HGF/c-Met pathway, while Semax is an ACTH fragment with Russian approval for cognitive indications. Neither is FDA-approved.

Key Facts

Aspect	Dihexa	Semax
Full Name	N-hexanoic-Tyr-Ile-(6) aminohexanoic amide	ACTH 4-10 + Pro-Gly-Pro
Structure	Hexapeptide derivative	7 amino acids
Mechanism	HGF/c-Met potentiator	BDNF, melanocortin-related
FDA Status	Not approved	Not approved
Other Approvals	None	Russia

Mechanism Comparison

Aspect	Dihexa	Semax
Primary Target	HGF/c-Met pathway	Melanocortin system, BDNF
Derived From	Angiotensin IV	ACTH (4-7) fragment
Proposed Action	Enhances HGF signaling	Neuroprotection, neuroplasticity
Receptor	c-Met (via HGF potentiation)	MC4R and others

How They Work

Dihexa:

• Developed as cognitive enhancer
• Potentiates hepatocyte growth factor (HGF)
• HGF/c-Met important for neuronal health
• Claimed to be extremely potent
• Very limited research

Semax:

• ACTH fragment without hormonal effects
• May increase BDNF expression
• Affects monoamine systems
• Neuroprotective claims
• Some clinical use in Russia

Evidence Comparison

Aspect	Dihexa	Semax
Human Trials	None	Some (Russia)
Animal Studies	Limited (one group)	Multiple
Publication Count	Very few	Moderate
Independent Replication	None	Limited

Dihexa Evidence Issues

• Research primarily from original patent holders
• No independent replication
• No human trials conducted
• Extraordinary potency claims unverified
• HGF/c-Met involvement in cancer raises safety questions

Semax Evidence Limitations

• Most research from Russia
• Limited Western peer review
• Methodology questions
• Clinical trial standards unclear

Claimed Effects

Dihexa (Unverified)

Claim	Evidence Level
Cognitive enhancement	Animal studies only
Synaptogenesis	In vitro, animal
Memory improvement	Animal studies
Extreme potency	Unverified

Semax (Limited Verification)

Claim	Evidence Level
Cognitive enhancement	Russian clinical use
Stroke recovery	Russian indication
Neuroprotection	Animal/some human
ADHD improvement	Russian use

Safety Concerns

Dihexa

Concern	Basis
HGF/c-Met in cancer	This pathway promotes tumor growth
No safety data	No human testing
Potency claims	Picomolar activity concerning
Quality	Gray market only

Critical concern: HGF/c-Met pathway is implicated in cancer progression. Enhancing this pathway chronically could theoretically promote tumor growth.

Semax

Concern	Basis
Limited Western data	Quality of Russian trials unclear
Long-term effects	Not well characterized
Drug interactions	Unknown
Quality outside Russia	Variable

Regulatory Status

Aspect	Dihexa	Semax
FDA Status	Not approved	Not approved
Russia	Not approved	Approved
Development Status	Abandoned	No Western development
WADA Status	Not listed	Not listed

Administration

Aspect	Dihexa	Semax
Route	Oral (claimed), SC	Intranasal
Stability	Unknown	Short half-life

Quality and Access

Factor	Dihexa	Semax
Pharmaceutical Grade	No	Yes (Russia)
Research Chemical	Yes	Yes
Quality Control	None	Variable
Purity Verification	Difficult	Possible (some sources)

Key Differences

Factor	Dihexa	Semax
Mechanism	HGF/c-Met	ACTH/melanocortin
Evidence Level	Very low	Moderate
Human Data	None	Some (Russia)
Regulatory Status	None	Russian approval
Safety Concerns	Significant (cancer pathway)	Lower
Research Base	Single group	Multiple groups

Risk Assessment

Factor	Dihexa	Semax
Evidence	Very weak	Weak
Safety profile	Unknown, concerning	Better characterized
Cancer pathway concern	Yes	No
Responsible choice	Higher risk	Lower risk

Summary

• Dihexa has interesting preclinical claims but no human data and significant safety concerns (HGF/c-Met cancer pathway)
• Semax has Russian approval and clinical use, providing more (though still limited) evidence
• Dihexa’s mechanism involves a known oncogenic pathway
• Semax has a cleaner safety profile despite limited Western data
• Neither is FDA-approved
• Dihexa’s extraordinary potency claims are unverified
• Research chemical quality is uncertain for both

---

This comparison is for educational purposes only. Neither compound is FDA-approved. Dihexa has no human safety data and works through a pathway involved in cancer. Products sold as research chemicals have uncertain quality and safety.